BRIEF-Sorrento, 3Sbio announce CAR-T joint venture in China

June 7 (Reuters) - Sorrento Therapeutics Inc

* 3Sbio will make total contributions of $10 million to

joint venture

* 3Sbio will initially own 51% of joint venture while TNK

will initially hold remaining 49%.

* tnk will grant JV exclusive license to CEA CAR-T

technology and two additional CARS for cellular therapy for

greater china market

* Sorrento And 3Sbio Announce CAR-T joint venture in China

Source text for Eikon:

Further company coverage:

(Bengaluru Newsroom: +1-646-223-8780)